Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: A case report

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Bezan, Angelika ^a   Hohla, Florian ^a   Meissnitzer, Thomas ^a   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Ascites; Catumaxomab; Colorectal cancer; Immunotherapy; Systemic effect

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CATUMAXOMAB; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; AGED; ARTICLE; CARCINOMATOUS PERITONITIS; CASE REPORT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GENE MUTATION; HEMICOLECTOMY; HUMAN; HYDRONEPHROSIS; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; MALE; MALIGNANT ASCITES; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT;

AGED; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; PERITONEAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84891366839     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-618     Document Type: Article

References (16)

1. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006, 243(2):212-222. 10.1097/01.sla.0000197702.46394.16, 1448921, 16432354.
2. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88(2):358-363. 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O, 10640968.
3. Klaver YL, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options. World J Gastroenterol 2012, 18(39):5489-5494. 10.3748/wjg.v18.i39.5489, 3482634, 23112540.
4. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996, 83(1):6-14. 10.1002/bjs.1800830104, 8653366.
5. Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 2011, 64(5):415-420. 10.1136/jcp.2011.090274, 3088404, 21415054.
6. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010, 127(9):2209-2221. 10.1002/ijc.25423, 2958458, 20473913.
7. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001, 98(8):2526-2534. 10.1182/blood.V98.8.2526, 11588051.
8. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A, Laimer K, Gastl G, Tzankov A, Spizzo G. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2008, 61(1):31-35.
9. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006, 103(2):483-488. 10.1016/j.ygyno.2006.03.035, 16678891.
10. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D, Zitt M, Brunhuber T, Schafer G, Gastl G, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 2004, 10(9):3131-3136. 10.1158/1078-0432.CCR-03-0528, 15131054.
11. Petrelli F, Borgonovo K, Lonati V, Elia S, Barni S. Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Target Oncol 2013, 8(4):291-294. 10.1007/s11523-012-0240-y, 23197249.
12. Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J. Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med Oncol 2012, 29(5):3416-3420. 10.1007/s12032-012-0285-x, 22744709.
13. Ruf P, Kluge M, Jager M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol 2010, 69(6):617-625. 10.1111/j.1365-2125.2010.03635.x, 2878603,2878603, 20565453.
14. Strohlein MA, Siegel R, Jager M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009, 28:18. 10.1186/1756-9966-28-18, 2644666, 19216794.
15. Ott MG, Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 2012, 130(9):2195-2203. 10.1002/ijc.26258, 3415680, 21702044.
16. Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, et al. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO study group. Gynecol Oncol 2011, 123(1):27-32. 10.1016/j.ygyno.2011.06.004, 21733566.